Search - tctmd.com

Displaying 201 - 220 of 393

Sort: Relevancy | Date

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Yelin Zhao

September 13, 2014

News Conference News ESC 2014

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Todd Neale

August 30, 2014

News Daily News

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

L.A. McKeown

June 17, 2014

News Daily News

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

L.A. McKeown

June 17, 2014

News Daily News

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

May 30, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

Presentation EuroPCR 2014

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

Presenter: Hiroyoshi Yokoi

May 21, 2014

News Conference News EuroPCR 2014

EuroPCR Features PAD Therapies in Early Development and Real-World Use

Caitlin E. Cox

May 21, 2014

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Caitlin E. Cox

May 21, 2014

Presentation EuroPCR 2014

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Presenter: Jos? Ram?n L?pez-M?nguez

May 20, 2014

News Daily News

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

May 20, 2014

News Daily News

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

May 20, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Daily News

Los Balones liberadores de Fármacos Reducen la Reestenosis y la RLD en Pacientes Diabéticos con ICE

Yael L. Maxwell

February 26, 2014

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Presenter: Michael Joner

October 31, 2013

Advertisement

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

EuroPCR Features PAD Therapies in Early Development and Real-World Use

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

Los Balones liberadores de Fármacos Reducen la Reestenosis y la RLD en Pacientes Diabéticos con ICE

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content